2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow EC regimen: new trials by email Literature Review of EC regimen trials Research Report on EC regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast Epirubicin, Cyclophosphamide, Cyclophosphamide, Methotrexate, 5 FU, Capecitabine, Nab-Paclitaxel - Breast Cancer | Phase 2 / Phase 3 | Completed | GBG Forschungs GmbH | 400 | 2009-03-01 | 2016-02-10 |
| Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel - Breast Cancer | Phase 3 | Completed | GBG Forschungs GmbH | 2600 | 2007-10-01 | 2016-02-10 |
Breast Neoplasms (2)
Germany (2)
Gunter von Minckwitz, MD, Prof. (1) · Gunter von Minckwitz, Prof. (1) · Michael Untch, MD, Prof. (1)
PMID 22257523, PMID 22276820, PMID 25223482, PMID 29543566, PMID 29791287, PMID 34037241
2008 (1)